Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Protein Effect||gain of function - predicted|
|Gene Variant Descriptions||ERBB2 (HER2) L841V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L841V has not been biochemically characterized, but in two different cell lines, L841V induced increased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785) and demonstrated transformation in cell culture (PMID: 29967253) and therefore, is predicted to result in a gain of Erbb2 (Her2) protein function.|
|Associated Drug Resistance|
|Transcript||gDNA||cDNA||Protein||Source Database||Genome Build|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 L841V||Her2-receptor negative breast cancer||no benefit||Neratinib||Case Reports/Case Series||Actionable||In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 2.8 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926).||29420467|
|ERBB2 L841V||colorectal cancer||predicted - resistant||Neratinib||Case Reports/Case Series||Actionable||In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with colorectal cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926).||29420467|